Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Background PRX302 is a prostate specific antigen (PSA)–activated pore-forming protein toxin under development as a targeted approach for improving lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) without affecting sexual function. Objective To evaluate the safety and...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Format: | article |
| Published: |
2011
|
| Online Access: | http://hdl.handle.net/10725/2730 http://dx.doi.org/10.1016/j.eururo.2010.11.024 http://www.sciencedirect.com/science/article/pii/S0302283810010936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|